Concepts (127)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fertility Preservation | 7 | 2023 | 58 | 2.910 |
Why?
|
| Ovarian Reserve | 3 | 2023 | 11 | 1.220 |
Why?
|
| Infertility, Female | 3 | 2023 | 149 | 0.980 |
Why?
|
| Doxorubicin | 2 | 2023 | 303 | 0.900 |
Why?
|
| Anti-Mullerian Hormone | 3 | 2023 | 43 | 0.900 |
Why?
|
| Infertility, Male | 2 | 2022 | 296 | 0.780 |
Why?
|
| Semen Preservation | 1 | 2022 | 10 | 0.760 |
Why?
|
| Neoplasms | 4 | 2023 | 2952 | 0.660 |
Why?
|
| Directive Counseling | 1 | 2019 | 24 | 0.610 |
Why?
|
| Counseling | 1 | 2020 | 233 | 0.600 |
Why?
|
| Cryopreservation | 5 | 2022 | 70 | 0.540 |
Why?
|
| Fertilization in Vitro | 5 | 2024 | 161 | 0.530 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1348 | 0.520 |
Why?
|
| Patient Selection | 1 | 2020 | 730 | 0.510 |
Why?
|
| Ovulation Induction | 4 | 2024 | 42 | 0.480 |
Why?
|
| Preimplantation Diagnosis | 3 | 2014 | 27 | 0.450 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 629 | 0.390 |
Why?
|
| Breast Neoplasms | 2 | 2023 | 2675 | 0.390 |
Why?
|
| Granulosa Cells | 3 | 2022 | 140 | 0.320 |
Why?
|
| Cyclophosphamide | 2 | 2023 | 426 | 0.320 |
Why?
|
| Pregnancy | 14 | 2024 | 7536 | 0.290 |
Why?
|
| Oocytes | 3 | 2019 | 290 | 0.280 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2020 | 261 | 0.260 |
Why?
|
| Female | 24 | 2024 | 70691 | 0.250 |
Why?
|
| Blastocyst | 2 | 2013 | 78 | 0.240 |
Why?
|
| Sperm Injections, Intracytoplasmic | 2 | 2013 | 46 | 0.240 |
Why?
|
| Pregnancy, Ectopic | 1 | 2005 | 23 | 0.240 |
Why?
|
| Uterine Perforation | 1 | 2004 | 1 | 0.230 |
Why?
|
| Hysterosalpingography | 1 | 2004 | 6 | 0.230 |
Why?
|
| Chromosomes | 1 | 2004 | 139 | 0.210 |
Why?
|
| Aneuploidy | 1 | 2004 | 143 | 0.210 |
Why?
|
| Methotrexate | 1 | 2005 | 351 | 0.200 |
Why?
|
| Paclitaxel | 1 | 2023 | 140 | 0.200 |
Why?
|
| Humans | 25 | 2024 | 132055 | 0.190 |
Why?
|
| Embryo, Mammalian | 1 | 2004 | 441 | 0.190 |
Why?
|
| Endometrial Neoplasms | 2 | 2020 | 112 | 0.190 |
Why?
|
| Adult | 15 | 2024 | 31557 | 0.180 |
Why?
|
| Cell Nucleus | 1 | 2004 | 591 | 0.180 |
Why?
|
| Ovarian Diseases | 1 | 2021 | 27 | 0.180 |
Why?
|
| Young Adult | 4 | 2023 | 9938 | 0.180 |
Why?
|
| Translocation, Genetic | 1 | 2003 | 358 | 0.180 |
Why?
|
| Fertility | 1 | 2023 | 260 | 0.170 |
Why?
|
| Premenopause | 1 | 2020 | 40 | 0.170 |
Why?
|
| Conservative Treatment | 1 | 2020 | 40 | 0.170 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2020 | 66 | 0.160 |
Why?
|
| Uterus | 1 | 2024 | 547 | 0.160 |
Why?
|
| Gene Expression | 1 | 2004 | 1563 | 0.160 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2020 | 52 | 0.150 |
Why?
|
| Ultrasonography | 1 | 2024 | 988 | 0.150 |
Why?
|
| Vincristine | 1 | 2020 | 196 | 0.150 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2019 | 45 | 0.150 |
Why?
|
| Estrogens | 1 | 2020 | 435 | 0.140 |
Why?
|
| Vaccination | 1 | 2023 | 1017 | 0.140 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 235 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 212 | 0.130 |
Why?
|
| Embryo Transfer | 3 | 2024 | 56 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 478 | 0.130 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 462 | 0.120 |
Why?
|
| Cancer Survivors | 1 | 2019 | 250 | 0.120 |
Why?
|
| Retrospective Studies | 6 | 2024 | 17367 | 0.120 |
Why?
|
| BRCA2 Protein | 1 | 2014 | 51 | 0.110 |
Why?
|
| BRCA1 Protein | 1 | 2014 | 81 | 0.110 |
Why?
|
| Parents | 1 | 2019 | 1080 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2004 | 774 | 0.090 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 3753 | 0.090 |
Why?
|
| Obesity | 1 | 2020 | 2397 | 0.070 |
Why?
|
| Oogenesis | 1 | 2008 | 55 | 0.070 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2008 | 76 | 0.070 |
Why?
|
| Middle Aged | 3 | 2023 | 28979 | 0.060 |
Why?
|
| Menstrual Cycle | 1 | 2005 | 36 | 0.060 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2005 | 311 | 0.060 |
Why?
|
| Luteinizing Hormone | 1 | 2005 | 136 | 0.060 |
Why?
|
| Hyaluronan Synthases | 1 | 2004 | 12 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2024 | 5168 | 0.060 |
Why?
|
| Serum Amyloid P-Component | 1 | 2004 | 14 | 0.060 |
Why?
|
| Blastomeres | 1 | 2004 | 6 | 0.060 |
Why?
|
| Male | 4 | 2022 | 64944 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 66 | 0.060 |
Why?
|
| Pregnancy Rate | 1 | 2004 | 40 | 0.060 |
Why?
|
| Pregnancy Outcome | 2 | 2005 | 634 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2005 | 363 | 0.050 |
Why?
|
| Glucuronosyltransferase | 1 | 2004 | 62 | 0.050 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 127 | 0.050 |
Why?
|
| Sperm Motility | 1 | 2004 | 113 | 0.050 |
Why?
|
| Live Birth | 1 | 2023 | 72 | 0.050 |
Why?
|
| Embryo Implantation | 1 | 2005 | 231 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2003 | 121 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 294 | 0.050 |
Why?
|
| ROC Curve | 1 | 2004 | 600 | 0.050 |
Why?
|
| Acceleration | 1 | 2022 | 27 | 0.050 |
Why?
|
| Spermatozoa | 1 | 2004 | 243 | 0.050 |
Why?
|
| Follicular Fluid | 1 | 2021 | 8 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2004 | 464 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2003 | 372 | 0.040 |
Why?
|
| Wound Healing | 1 | 2004 | 475 | 0.040 |
Why?
|
| Georgia | 1 | 2019 | 39 | 0.040 |
Why?
|
| Proxy | 1 | 2019 | 21 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2004 | 523 | 0.040 |
Why?
|
| Reproductive Health | 1 | 2019 | 49 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2004 | 2312 | 0.040 |
Why?
|
| Age Distribution | 1 | 2019 | 433 | 0.030 |
Why?
|
| Endometrium | 1 | 2020 | 276 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 3984 | 0.030 |
Why?
|
| Adolescent | 3 | 2020 | 20530 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2004 | 1596 | 0.030 |
Why?
|
| Biomarkers | 2 | 2020 | 3403 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1294 | 0.030 |
Why?
|
| Cytokines | 1 | 2021 | 1365 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 3414 | 0.030 |
Why?
|
| Reproductive Behavior | 1 | 2013 | 7 | 0.030 |
Why?
|
| United States | 2 | 2020 | 11652 | 0.030 |
Why?
|
| Hot Temperature | 1 | 2013 | 141 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 3370 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2004 | 8539 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5407 | 0.020 |
Why?
|
| Prognosis | 1 | 2019 | 5013 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2014 | 1098 | 0.020 |
Why?
|
| Cell Survival | 1 | 2008 | 868 | 0.020 |
Why?
|
| Risk Factors | 1 | 2020 | 10936 | 0.020 |
Why?
|
| Texas | 1 | 2013 | 3632 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 437 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 588 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 3358 | 0.010 |
Why?
|
| Aged | 1 | 2019 | 21456 | 0.010 |
Why?
|
| Mutation | 1 | 2014 | 6246 | 0.010 |
Why?
|
| Prevalence | 1 | 2005 | 2662 | 0.010 |
Why?
|
| Animals | 1 | 2008 | 34823 | 0.000 |
Why?
|